Antiviral Drug Resistance Market Size, Growth, Share by 2031
The antiviral drug resistance market size is projected to reach US$ 6.35 billion by 2031 from US$ 3.44 billion in 2023. The market is expected to register a CAGR of 7.9% during 2023–2031. Rising in incidences of hepatic diseases, the prevalence of HIV and AIDS, and demand for high-quality products in emerging nations are likely to remain key trends in the market.
Antiviral Drug Resistance Market Analysis
The prevalence of HIV/AIDS has increased in recent years worldwide. Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition which is caused by a human immunodeficiency virus (HIV). The virus is responsible for damaging the immune system, where HIV interferes with the body's ability to fight the organisms that cause disease. When HIV enters the body, it develops a flu-like illness within a month. This illness is known as primary or acute HIV infection that may last for a few weeks. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), in 2022, approx. 39 million people were living worldwide with HIV/AIDS. A massive majority of people living with HIV are in low- and middle-income countries. For instance, according to the India HIV Estimation 2017 report (National Informatics Centre), in India, the prevalence of HIV is estimated at 0.22% (0.16%–0.30%). Moreover, an adult HIV prevalence is estimated at 0.25% (0.18%-0.34%) among males and at 0.19% (0.14-0.25) among Females. Hence, the cases of viral infections in the country are anticipated to drive the demand for the antiviral drug resistance market during the forecast period
Antiviral Drug Resistance Market Overview
Rise in the incidences of hepatitis diseases and increasing prevalence of HIV/AIDS are boosting the growth of the market over the years. Also, the increase in the emerging market is likely to have a positive impact on the demand for the market during the forecast period. However, the growth of the market is restrained by a factor such as alternative approaches. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Hence, the factors as mentioned above are anticipated to fuel the growth of North America antiviral drug resistance market during the forecast period.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Antiviral Drug Resistance Market: Strategic Insights
Market Size Value in US$ 2,572.26 Million in 2018 Market Size Value by US$ 4,573.24 Million by 2027 Growth rate CAGR of 6.8% from 2019-2027 Forecast Period 2019-2027 Base Year 2019
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Antiviral Drug Resistance Market: Strategic Insights
| Market Size Value in | US$ 2,572.26 Million in 2018 |
| Market Size Value by | US$ 4,573.24 Million by 2027 |
| Growth rate | CAGR of 6.8% from 2019-2027 |
| Forecast Period | 2019-2027 |
| Base Year | 2019 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Antiviral Drug Resistance Market Drivers and Opportunities
Rising Incidences of Hepatic Diseases to Favor Market
Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems. The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.
Increasing Healthcare Expenditures in Emerging Markets
The increasing healthcare expenditure in emerging economies such as Asia Pacific and South and Central America are enabling researchers to develop treatment options for a wide range of viral diseases by utilizing advanced techniques such as PCR (Polymerase Chain Reaction), next-generation sequencing, and others. Several organizations such as, National Cancer Institute (NCI) funded for HIV and AIDS Malignancies Research to study about how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer. China, Japan, Brazil and other emerging nations are spending heavily on healthcare expenditure to establish their presence in the market as well as to ensure the appropriate use of instruments and reagents used in hospitals and research institutes, pathological labs and other destinations in their respective countries.
Antiviral Drug Resistance Market Report Segmentation Analysis
Key segments that contributed to the derivation of the antiviral drug resistance market analysis are type, disease indication, technology, and end users.
- Based on type, the antiviral drug resistance market is divided into into kits and reagents and instruments. The kits and reagents segment held the largest share of the market in 2023.
- By disease indication, the market is segmented into HIV, hepatitis and Cytomegalovirus (CMV). The HIV segment held the largest share of the market in 2023.
- In terms of technology, the market is segmented into immunodiagnostics, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. The immunodiagnostics segment held a significant share of the market in 2023.
- Based on end users, the antiviral drug resistance market is divided into into hospitals and clinics, pathology or diagnostic laboratories and research institutes. The hospitals and clinics segment held the largest share of the market in 2023.
Antiviral Drug Resistance Market Share Analysis by Geography
The geographic scope of the antiviral drug resistance market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. North America has largest market share of the high-flow nasal cannula market, by geography. The demand for the market is anticipated to grow at a substantial rate during the forecast period owing to various factors such as prevalence of viral infections such as HIV and hepatitis, presence of national programmes and funding by government bodies. The prevalence of HIV in the US has increased during recent years. As per the data provided by the US Department of Health & Human Services and supported and the Secretary’s Minority AIDS Initiative Fund (SMAIF), almost 32,100 Americans were newly infected with HIV during 2021. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
Antiviral Drug Resistance Market Report Scope
Antiviral Drug Resistance Market News and Recent Developments
The antiviral drug resistance market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the antiviral drug resistance market are listed below:
- – The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies for the prevention and treatment of dengue. (Source: Johnson & Johnson, Press Release, March 2023)
- Cipla Limited announced that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease. (Source: Cipla, Press Release, May 2021)
Antiviral Drug Resistance Market Report Coverage and Deliverables
The “Antiviral Drug Resistance Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Antiviral Drug Resistance market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Antiviral Drug Resistance market trends, as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Antiviral Drug Resistance market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Antiviral Drug Resistance market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product , Disease Indication , Technology , End User , and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Frequently Asked Questions
Based on geography, the antiviral drug resistance market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global antiviral drug resistance market. Asia Pacific is expected to register the highest CAGR in the antiviral drug resistance market during 2023–2031
Risisng in the incidences of hepatitis diseases followed by increasing prevalence of HIV and AIDS largely drive the antiviral drug resistance market size
The Antiviral Drug Resistance market majorly consists of players such AccuBioTech Co., Ltd.; ACON Laboratories, Inc.; Siemens AG; BioMérieux SA; Bio-Rad Laboratories, Inc.; Danaher; Abbott; BDF. Hoffmann-La Roche Ltd.; and Trinity Biotech.
The antiviral drug resistance market size is projected to reach US$ 6.35 billion by 2031
The market is expected to register a CAGR of 7.9% during 2023–2031
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For